Indomethacin (Tocolytic) — Discount Pricing

Other medications in Women's Health

• Letrozole (Infertility)
• Levonorgestrel IUD
• Levonorgestrel-Ethinyl Estradiol
• Magnesium Sulfate
• Medroxyprogesterone Injection
• Methylergonovine
• Mifepristone
• Misoprostol Cervical

About Indomethacin (Tocolytic)

Indomethacin, when used as a tocolytic, plays a crucial role in the short-term management of preterm labor, offering a window to improve fetal outcomes. Understanding this medication is key for expectant parents and healthcare providers. At TheDrugClub, we believe in making essential medications more accessible and affordable, helping our members save significantly on prescriptions like indomethacin.

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that finds an important, albeit off-label, use as a tocolytic. A tocolytic is a medication designed to suppress uterine contractions and delay preterm labor. This critical delay can provide valuable time for interventions like administering corticosteroids to the mother, which helps accelerate fetal lung development, or facilitating a safe transfer to a facility equipped for high-risk deliveries. It is typically used for short durations, usually no more than 48-72 hours, and generally between 24 and 32 weeks of gestation, due to potential risks to the fetus with prolonged use or use later in pregnancy.

How Indomethacin Works to Delay Labor

The mechanism behind indomethacin's tocolytic action lies in its ability to inhibit prostaglandin synthesis. Prostaglandins are hormone-like compounds that play a significant role in initiating and maintaining labor contractions. By blocking the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), indomethacin reduces the production of these prostaglandins in the uterus. This reduction in prostaglandin levels decreases the intensity and frequency of uterine contractions, thereby helping to delay preterm labor.

Typical Costs of Indomethacin

The cost of indomethacin can vary based on the dosage, quantity prescribed, the specific pharmacy, and your geographic location. As a generic medication, indomethacin is generally more affordable than brand-name alternatives. Without insurance or a discount program, a typical prescription for a short course of indomethacin might range anywhere from $20 to $60, though these are estimates and prices can fluctuate. These costs can be a concern

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Indomethacin (Tocolytic) is approved for (FDA label)

Indomethacin extended-release capsules are indicated for: • Moderate to severe rheumatoid arthritis including acute flares of chronic disease • Moderate to severe ankylosing spondylitis • Moderate to severe osteoarthritis • Acute painful shoulder (bursitis and/or tendinitis) Indomethacin extended-release capsules are a nonsteroidal anti-inflammatory drug indicated for: • Moderate to severe rheumatoid arthritis including acute flares of chronic disease • Moderate to severe ankylosing spondylitis • Moderate to severe osteoarthritis • Acute painful shoulder (bursitis and/or tendinitis) ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 17, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Indomethacin (Tocolytic) (FDA label)

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1) ]. • Indomethacin extended-release capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1) ]. Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2) ]. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

Source: FDA prescribing information (DailyMed). Set ID: 12821a3a-b5f2-4415-84c9-0a30a4725f1e. SPL document ID: 59413a4c-b487-26f8-e063-6394a90aed07. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Indomethacin (Tocolytic) (FDA label)

Indomethacin extended-release capsules USP, 75 mg are size ‘2’, dark yellow cap and clear transparent body hard gelatin capsules, containing cream spherical pellets imprinted with ‘H’ on cap and ‘105’ on body. Indomethacin extended-release capsules USP: 75 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 12821a3a-b5f2-4415-84c9-0a30a4725f1e. SPL document ID: 59413a4c-b487-26f8-e063-6394a90aed07. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Indomethacin (Tocolytic) (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: • Cardiovascular Thrombotic Events [see Warnings and Precautions (5.1) ] • GI Bleeding, Ulceration and Perforation [see Warnings and Precautions (5.2) ] • Hepatotoxicity [see Warnings and Precautions (5.3) ] • Hypertension [see Warnings and Precautions (5.4) ] • Heart Failure and Edema [see Warnings and Precautions (5.5) ] • Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.6) ] • Anaphylactic Reactions [see Warnings and Precautions (5.7) ] • Serious Skin Reactions [see Warnings and Precautions (5.9) ] • Hematologic Toxicity [see Warnings and Precautions (5.12) ] Most common adverse reactions (incidence ≥ 3%) are headache, dizziness, dyspepsia and nausea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 12821a3a-b5f2-4415-84c9-0a30a4725f1e. SPL document ID: 59413a4c-b487-26f8-e063-6394a90aed07. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Indomethacin (Tocolytic) (FDA label)

Indomethacin extended-release capsules are contraindicated in the following patients: • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to indomethacin or any components of the drug product [see Warnings and Precautions (5.7 , 5.9 )] • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.7 , 5.8) ] • In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1) ] • Known hypersensitivity to indomethacin or any components of the drug product ( 4 ) • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs ( 4 ) • In the setting of CABG surgery ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 12821a3a-b5f2-4415-84c9-0a30a4725f1e. SPL document ID: 59413a4c-b487-26f8-e063-6394a90aed07. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Indomethacin (Tocolytic) (FDA label)

• Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop ( 5.3 ) • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure ( 5.4 , 7 ) • Heart Failure and Edema : Avoid use of indomethacin extended-release capsules in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure ( 5.5 ) • Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia.

Source: FDA prescribing information (DailyMed). Set ID: 12821a3a-b5f2-4415-84c9-0a30a4725f1e. SPL document ID: 59413a4c-b487-26f8-e063-6394a90aed07. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Indomethacin (Tocolytic) (FDA label)

See Table 2 for clinically significant drug interactions with indomethacin. Table 2 Clinically Significant Drug Interactions with Indomethacin Dr ugs That Interfere with Hemostasis C linica l Impact: Indomethacin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of indomethacin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.

Source: FDA prescribing information (DailyMed). Set ID: 12821a3a-b5f2-4415-84c9-0a30a4725f1e. SPL document ID: 59413a4c-b487-26f8-e063-6394a90aed07. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.